Scientific work

Doç. Dr. Yasin Kutlu

54 publications. The source of the information is stated next to each publication.

Back to profile

  1. Resection and pathological response after neoadjuvant nivolumab plus chemotherapy for lung cancer in a Turkish Oncology Group (TOG) real-world study

    Research Square, 2026

    DOI 10.21203/rs.3.rs-11204389/v1 Open-access full textSource: OpenAlex

  2. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062406 PMID 41899326 Open-access full textSource: OpenAlex

  3. Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy

    Pharmaceuticals, 2026

    DOI 10.3390/ph19040587 PMID 42075843 Open-access full textSource: OpenAlex

  4. A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15083118 PMID 42074920 Open-access full textSource: OpenAlex

  5. Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study

    Journal of Immunotherapy, 2026

    DOI 10.1097/cji.0000000000000610 PMID 42267536 Source: OpenAlex

  6. Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

    Clinical & Translational Oncology, 2026

    DOI 10.1007/s12094-026-04494-3 PMID 42400766 Source: OpenAlex

  7. Revisiting Platinum Sensitivity in Relapsed Small-Cell Lung Cancer: Outcomes of Platinum-Containing Doublet Chemotherapy in the 3–6 Month Relapse Window

    Current Oncology, 2026

    DOI 10.3390/curroncol33080472 PMID 42645377 Open-access full textSource: OpenAlex

  8. Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer

    OncoImmunology, 2026

    DOI 10.1080/2162402x.2026.2738262 PMID 42788839 Open-access full textSource: OpenAlex

  9. Predictive and Prognostic Value of Androgen Receptor Expression Across All Molecular Subtypes in Patients with Breast Cancer Who Received Neoadjuvant-Treatment: Single-Center Retrospective Analysis

    Breast Cancer Targets and Therapy, 2026

    DOI 10.2147/bctt.s647399 PMID 42936308 Open-access full textSource: OpenAlex

  10. Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-09707-3 PMID 40653542 5 citations (Europe PMC) Open-access full textSource: OpenAlex

  11. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

    Medicina, 2025

    DOI 10.3390/medicina61030490 PMID 40142301 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  12. Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2358458 PMID 38803194 Source: OpenAlex

  13. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study

    Cancers, 2024

    DOI 10.3390/cancers16122251 PMID 38927957 4 citations (Europe PMC) Open-access full textSource: OpenAlex

  14. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

    International Journal of Clinical Oncology, 2024

    DOI 10.1007/s10147-023-02460-5 PMID 38310597 6 citations (Europe PMC) Source: OpenAlex

  15. Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer

    Current Problems in Cancer, 2024

    DOI 10.1016/j.currproblcancer.2024.101102 PMID 38735211 2 citations (Europe PMC) Source: OpenAlex

  16. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study

    Expert Opinion on Pharmacotherapy, 2024

    DOI 10.1080/14656566.2024.2337261 PMID 38568074 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  17. 71P The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: A Turkish Oncology Group (TOG) study

    ESMO Open, 2024

    DOI 10.1016/j.esmoop.2024.102300 Open-access full textSource: OpenAlex

  18. Erken Evre Küçük Hücreli Dışı Akciğer Kanserinde Neoadjuvan Tedavilerin Etkinliği: Tek Merkez Deneyimi

    Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2024

    DOI 10.32708/uutfd.1515582 Open-access full textSource: OpenAlex

  19. Real-World Outcomes Of Lu-177 PSMA In Patients With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Experience

    Research Square, 2023

    DOI 10.21203/rs.3.rs-3365105/v1 Open-access full textSource: OpenAlex

  20. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy

    Medicine, 2023

    DOI 10.1097/md.0000000000033432 PMID 37058061 14 citations (Europe PMC) Open-access full textSource: OpenAlex

  21. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

    Cancer Chemotherapy and Pharmacology, 2023

    DOI 10.1007/s00280-023-04592-x PMID 37773537 8 citations (Europe PMC) Source: OpenAlex

  22. Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer

    International Immunopharmacology, 2023

    DOI 10.1016/j.intimp.2023.110947 PMID 37742369 5 citations (Europe PMC) Source: OpenAlex

  23. Integrated FDG-PET/CT contribution over cross-sectional imaging in recurrence or progression of pancreaticobiliary neoplasms

    Abdominal Radiology, 2023

    DOI 10.1007/s00261-023-04109-3 PMID 37991533 1 citation (Europe PMC) Source: OpenAlex

  24. SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT

    Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi, 2023

    DOI 10.26650/iuitfd.1211556 Open-access full textSource: OpenAlex

  25. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data

    Journal of Gastrointestinal Cancer, 2023

    DOI 10.1007/s12029-023-00953-0 PMID 37347353 1 citation (Europe PMC) Source: OpenAlex

  26. The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients

    Acta Oncologica Turcica, 2023

    DOI 10.5505/aot.2023.00187 Open-access full textSource: OpenAlex

  27. Erken Evre Triple Negatif Meme Kanserinde Sağkalım Sonuçları ve Prognostik Faktörler: Tek Merkez Deneyimi

    Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2023

    DOI 10.32708/uutfd.1356458 Open-access full textSource: OpenAlex

  28. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

    Future Oncology, 2022

    DOI 10.2217/fon-2022-0083 PMID 35734870 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  29. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04087-x PMID 35689097 11 citations (Europe PMC) Open-access full textSource: OpenAlex

  30. The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer

    Breast Care, 2022

    DOI 10.1159/000524446 PMID 36684400 7 citations (Europe PMC) Open-access full textSource: OpenAlex

  31. Diagnostic and prognostic value of Nesfatin-1 in sepsis and septic shock

    Journal of Experimental and Clinical Medicine, 2022

    DOI 10.52142/omujecm.39.1.1 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  32. THE RELATIONSHIP BETWEEN sTREM-1 AND ACTIVATION OF INFLAMMATORY BOWEL DISEASES

    Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi, 2021

    DOI 10.26650/iuitfd.2020.0090 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  33. P40.20 Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients With Metastatic Non-Small Cell Lung Cancer

    Journal of Thoracic Oncology, 2021

    DOI 10.1016/j.jtho.2021.08.457 Open-access full textSource: OpenAlex

  34. Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer

    Acta Oncologica Turcica, 2021

    DOI 10.5505/aot.2021.26576 Open-access full textSource: OpenAlex

  35. The relationship between insulin resistance, obesity, and endotrophin

    International Journal of Diabetes in Developing Countries, 2020

    DOI 10.1007/s13410-019-00780-9 5 citations (OpenAlex) Source: OpenAlex

  36. Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease

    Medical Principles and Practice, 2019

    DOI 10.1159/000500106 PMID 30995640 34 citations (Europe PMC) Open-access full textSource: OpenAlex

  37. Serum endotrophin levels in patients with heart failure with reduced and mid-range ejection fraction

    European Journal of Internal Medicine, 2019

    DOI 10.1016/j.ejim.2019.04.016 PMID 31036437 8 citations (Europe PMC) Source: OpenAlex

  38. Reply to the Letter to the Editor “Adropin: Connection between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease”

    Medical Principles and Practice, 2019

    DOI 10.1159/000502106 PMID 31505512 Open-access full textSource: OpenAlex

  39. Serum endotrophin levels in heart failure patients with reduced ejection fraction; a preliminary study

    2019

    Source: OpenAlex

  40. Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients

    International Urology and Nephrology, 2017

    DOI 10.1007/s11255-017-1556-4 PMID 28255639 12 citations (Europe PMC) Source: OpenAlex

  41. 7.6. Ulusal bilimsel toplantılarda sunulan ve bildiri kitabında basılan bildiriler

    Source: medipol.com.tr profile page

  42. 7.1. Uluslararası hakemli dergilerde yayınlanan makaleler (SCI & SSCI & Arts and Humanities)

    Source: medipol.com.tr profile page

  43. 7.2. Uluslararası diğer hakemli dergilerde yayınlanan makaleler

    Source: medipol.com.tr profile page

  44. 7.3. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler

    Source: medipol.com.tr profile page

  45. 7.4. Yazılan uluslararası kitaplar veya kitaplarda bölümler

    Source: medipol.com.tr profile page

  46. 7.5. Ulusal hakemli dergilerde yayınlanan makaleler

    Source: medipol.com.tr profile page

  47. 7.7. Diğer yayınlar

    Source: medipol.com.tr profile page

  48. 7. Yayınlar

    Source: medipol.com.tr profile page

  49. 2. Arman, Y., Ugurlukisi, B., Yuruyen, G., Akarsu, M., Kose, M., Cil, E. O., Ozcan, M., Saracoglu, B., Toprak, ID., Kutlu, Y., Toprak, Z., Alibeyoglu, A., Yoldemir, S., Altun, O., Tukek, T. (2016). The effect of blood glucose regulation on ironmetabolism and hepcidin in uncontrolled type 2 diabetic patients. Int J Clin Exp Med, 9(2), 3869-76.

    Source: medipol.com.tr profile page

  50. 3. Yürüyen, G., Toprak, İ. D., & Kutlu, Y. (2019). Adult vaccination awareness in physicians. Bosphorus Medical Journal, 6(3), 89-93.

    Source: medipol.com.tr profile page